search
Back to results

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

Primary Purpose

Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Proton Beam Radiation
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Cancer focused on measuring proton beam irradiation, liver cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
  • Primary lesion size of 6cm or less in greatest diameter
  • Single or multinodular tumors (up to 3)
  • 18 years of age or older
  • No evidence of extrahepatic tumor
  • Karnofsky performance status of 70-100
  • If patient has underlying cirrhosis, only Child's classification Group A or Group B
  • Adequate renal function
  • Expected survival of greater than three months

Exclusion Criteria:

  • Pregnant or lactating women
  • Evidence of non-hepatic metastatic disease
  • Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
  • Prior radiation treatment to affected region
  • Serious psychiatric illness which would limit compliance with treatment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Proton Beam Radiation

    Arm Description

    Proton radiation therapy

    Outcomes

    Primary Outcome Measures

    To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.

    Secondary Outcome Measures

    To determine safety and tolerance of this treatment program
    to evaluate tumor response, local control and survival in this patient population.

    Full Information

    First Posted
    April 23, 2007
    Last Updated
    January 19, 2017
    Sponsor
    Massachusetts General Hospital
    Collaborators
    National Cancer Institute (NCI), Dana-Farber Cancer Institute, Brigham and Women's Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00465023
    Brief Title
    Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
    Official Title
    Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2003 (undefined)
    Primary Completion Date
    September 2013 (Actual)
    Study Completion Date
    January 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Massachusetts General Hospital
    Collaborators
    National Cancer Institute (NCI), Dana-Farber Cancer Institute, Brigham and Women's Hospital

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.
    Detailed Description
    Participants will receive treatment as an outpatient at the Northeast Proton Treatment Center located at the Massachusetts General Hospital. Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects. Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes. A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
    Keywords
    proton beam irradiation, liver cancer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    16 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Proton Beam Radiation
    Arm Type
    Experimental
    Arm Description
    Proton radiation therapy
    Intervention Type
    Procedure
    Intervention Name(s)
    Proton Beam Radiation
    Intervention Description
    Once a day, 5 days a week (Monday-Friday) for 3 weeks.
    Primary Outcome Measure Information:
    Title
    To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
    Time Frame
    4 years
    Secondary Outcome Measure Information:
    Title
    To determine safety and tolerance of this treatment program
    Time Frame
    4 years
    Title
    to evaluate tumor response, local control and survival in this patient population.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases. Primary lesion size of 6cm or less in greatest diameter Single or multinodular tumors (up to 3) 18 years of age or older No evidence of extrahepatic tumor Karnofsky performance status of 70-100 If patient has underlying cirrhosis, only Child's classification Group A or Group B Adequate renal function Expected survival of greater than three months Exclusion Criteria: Pregnant or lactating women Evidence of non-hepatic metastatic disease Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc. Prior radiation treatment to affected region Serious psychiatric illness which would limit compliance with treatment
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Theodore S. Hong, MD
    Organizational Affiliation
    Massachusetts General Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

    We'll reach out to this number within 24 hrs